Next earnings date: 12 Aug 2025
CEL-SCI Corporation – AMEX:CVM
CEL-SCI stock price today
$8.63
+8.02
+1338.09%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
CEL-SCI stock price monthly change
-53.13%
month
CEL-SCI stock price quarterly change
-53.13%
quarter
CEL-SCI stock price yearly change
-79.93%
year
CEL-SCI key metrics
Market Cap | 48.39M |
Enterprise value | 100.69M |
P/E | -2.85 |
EV/Sales | N/A |
EV/EBITDA | -3.14 |
Price/Sales | N/A |
Price/Book | 3.90 |
PEG ratio | -0.85 |
EPS | -0.69 |
Revenue | N/A |
EBITDA | -26.93M |
Income | -31.75M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCEL-SCI stock price history
CEL-SCI stock forecast
CEL-SCI financial statements
| Mar 2023 | 0 | -8.50M | |
|---|---|---|---|
| Jun 2023 | 0 | -8.36M | |
| Sep 2023 | 0 | -7.63M | |
| Mar 2024 | 0 | -7.24M |
| 2027 | 156.1M | -6.67M | -4.27% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-08-14 | -0.13 | -0.14 |
|---|
| Mar 2023 | 38195243 | 18.04M | 47.25% |
|---|---|---|---|
| Jun 2023 | 32318968 | 17.52M | 54.24% |
| Sep 2023 | 30528250 | 17.31M | 56.71% |
| Mar 2024 | 30048105 | 15.74M | 52.39% |
| Mar 2023 | -7.47M | -111.45K | -388 |
|---|---|---|---|
| Jun 2023 | -5.66M | -196.86K | 951 |
| Sep 2023 | -5.04M | -10.37K | 4.06K |
| Mar 2024 | -4.52M | 0 | 6.59M |
CEL-SCI alternative data
| Aug 2023 | 43 |
|---|---|
| Sep 2023 | 43 |
| Oct 2023 | 43 |
| Nov 2023 | 43 |
| Dec 2023 | 43 |
| Jan 2024 | 43 |
| Feb 2024 | 43 |
| Mar 2024 | 43 |
| Apr 2024 | 43 |
| May 2024 | 43 |
| Jun 2024 | 43 |
| Jul 2024 | 43 |
CEL-SCI other data
5.37%
-8.03%
of CVM is owned by hedge funds
40
-36
2.38M
-3.39M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 58000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | KERSTEN GEERT R director, officer.. | Common Stock | 30,000 | $1.39 | $41,700 | ||
Purchase | PRICHEP PATRICIA B officer: Senior V.. | Common Stock | 8,000 | $1.39 | $11,120 | ||
Purchase | WATSON ROBERT EUGENE director | Common Stock | 20,000 | $1.39 | $27,800 | ||
Sale | TALOR EYAL officer: Chief Sc.. | Common Stock | 15,000 | $11.25 | $168,750 | ||
Purchase | KERSTEN GEERT R director, officer.. | Common Stock | 25,000 | N/A | N/A | ||
Purchase | BAILLAVOINE BRUNO JEAN-MARIE director | Common Stock | 1,250 | N/A | N/A | ||
Purchase | WATSON ROBERT EUGENE director | Common Stock | 1,250 | $8 | $10,000 | ||
Purchase | YOUNG PETER R director | Common Stock | 3,000 | $12.66 | $37,971 | ||
Sale | CIPRIANO JOHN officer: Senior V.. | Common Stock | 10,000 | $24.38 | $243,790 | ||
Purchase | YOUNG PETER R director | Common Stock | 100 | N/A | N/A |
-
What's the price of CEL-SCI stock today?
One share of CEL-SCI stock can currently be purchased for approximately $8.63.
-
When is CEL-SCI's next earnings date?
CEL-SCI Corporation is estimated to report earnings on Tuesday, 12 Aug 2025.
-
Does CEL-SCI pay dividends?
No, CEL-SCI does not pay dividends.
-
How much money does CEL-SCI make?
CEL-SCI has a market capitalization of 48.39M. CEL-SCI made a loss 32.37M US dollars in net income (profit) last year or -$0.14 on an earnings per share basis.
-
What is CEL-SCI's stock symbol?
CEL-SCI Corporation is traded on the AMEX under the ticker symbol "CVM".
-
What is CEL-SCI's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CEL-SCI?
Shares of CEL-SCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the following people:
- Mr. Geert R. Kersten Chief Executive Officer, Principal Accounting & Financial Officer, Treasurer and Director(age: 66, pay: $675,650)
- Dr. Eyal Talor Ph.D. Chief Scientific Officer(age: 69, pay: $320,860)
- Ms. Patricia B. Prichep Senior Vice President of Operations & Corporation Sec.(age: 74, pay: $270,050)
- Dr. Daniel H. Zimmerman Ph.D. Senior Vice President of Research & Cellular Immunology(age: 84, pay: $249,010)
- Mr. John Cipriano Senior Vice President of Regulatory Affairs(age: 83, pay: $225,360)
-
How many employees does CEL-SCI have?
As Jul 2024, CEL-SCI employs 43 workers.
-
When CEL-SCI went public?
CEL-SCI Corporation is publicly traded company for more then 41 years since IPO on 8 Dec 1983.
-
What is CEL-SCI's official website?
The official website for CEL-SCI is cel-sci.com.
-
Where are CEL-SCI's headquarters?
CEL-SCI is headquartered at 8229 Boone Boulevard, Vienna, VA.
-
How can i contact CEL-SCI?
CEL-SCI's mailing address is 8229 Boone Boulevard, Vienna, VA and company can be reached via phone at +7 035069460.
CEL-SCI company profile:
CEL-SCI Corporation
cel-sci.comExchange:
AMEX
Full time employees:
43
Industry:
Biotechnology
Sector:
Healthcare
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
8229 Boone Boulevard
Vienna, VA 22182
Vienna, VA 22182
CIK: 0000725363
ISIN: US1508376076
CUSIP: 150837607
